BR112016017679A2 - - Google Patents

Info

Publication number
BR112016017679A2
BR112016017679A2 BR112016017679A BR112016017679A BR112016017679A2 BR 112016017679 A2 BR112016017679 A2 BR 112016017679A2 BR 112016017679 A BR112016017679 A BR 112016017679A BR 112016017679 A BR112016017679 A BR 112016017679A BR 112016017679 A2 BR112016017679 A2 BR 112016017679A2
Authority
BR
Brazil
Application number
BR112016017679A
Other languages
Portuguese (pt)
Other versions
BR112016017679B1 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of BR112016017679A2 publication Critical patent/BR112016017679A2/pt
Publication of BR112016017679B1 publication Critical patent/BR112016017679B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112016017679-0A 2014-02-21 2015-02-20 Compostos derivados de 5-benzilisoquinolina para o tratamento de doenças cardiovasculares, processo para a síntese dos referidos compostos e composição farmacêutica os contendo BR112016017679B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1451389 2014-02-21
FR1451389A FR3017868A1 (fr) 2014-02-21 2014-02-21 Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PCT/FR2015/050415 WO2015124877A1 (fr) 2014-02-21 2015-02-20 Dérivés de 5-benzylisoquinoléine pour le traitement de maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
BR112016017679A2 true BR112016017679A2 (cg-RX-API-DMAC10.html) 2017-08-08
BR112016017679B1 BR112016017679B1 (pt) 2022-07-26

Family

ID=50424640

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016017679-0A BR112016017679B1 (pt) 2014-02-21 2015-02-20 Compostos derivados de 5-benzilisoquinolina para o tratamento de doenças cardiovasculares, processo para a síntese dos referidos compostos e composição farmacêutica os contendo

Country Status (37)

Country Link
US (1) US9809553B2 (cg-RX-API-DMAC10.html)
EP (1) EP3107900B1 (cg-RX-API-DMAC10.html)
JP (1) JP6491226B2 (cg-RX-API-DMAC10.html)
KR (1) KR102251198B1 (cg-RX-API-DMAC10.html)
CN (1) CN105980361B (cg-RX-API-DMAC10.html)
AR (1) AR099493A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015220659B2 (cg-RX-API-DMAC10.html)
BR (1) BR112016017679B1 (cg-RX-API-DMAC10.html)
CA (1) CA2938344C (cg-RX-API-DMAC10.html)
CL (1) CL2016002089A1 (cg-RX-API-DMAC10.html)
CY (1) CY1120034T1 (cg-RX-API-DMAC10.html)
DK (1) DK3107900T3 (cg-RX-API-DMAC10.html)
EA (1) EA030617B1 (cg-RX-API-DMAC10.html)
ES (1) ES2659885T3 (cg-RX-API-DMAC10.html)
FR (1) FR3017868A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20180141T1 (cg-RX-API-DMAC10.html)
HU (1) HUE038337T2 (cg-RX-API-DMAC10.html)
IL (1) IL246721B (cg-RX-API-DMAC10.html)
JO (1) JO3372B1 (cg-RX-API-DMAC10.html)
LT (1) LT3107900T (cg-RX-API-DMAC10.html)
MA (1) MA39207A1 (cg-RX-API-DMAC10.html)
ME (1) ME02863B (cg-RX-API-DMAC10.html)
MX (1) MX363301B (cg-RX-API-DMAC10.html)
MY (1) MY178745A (cg-RX-API-DMAC10.html)
NO (1) NO3107900T3 (cg-RX-API-DMAC10.html)
NZ (1) NZ722513A (cg-RX-API-DMAC10.html)
PL (1) PL3107900T3 (cg-RX-API-DMAC10.html)
PT (1) PT3107900T (cg-RX-API-DMAC10.html)
RS (1) RS56766B1 (cg-RX-API-DMAC10.html)
RU (1) RU2679621C2 (cg-RX-API-DMAC10.html)
SG (1) SG11201605662TA (cg-RX-API-DMAC10.html)
SI (1) SI3107900T1 (cg-RX-API-DMAC10.html)
TW (1) TWI547484B (cg-RX-API-DMAC10.html)
UA (1) UA117953C2 (cg-RX-API-DMAC10.html)
UY (1) UY35997A (cg-RX-API-DMAC10.html)
WO (1) WO2015124877A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201604976B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10640496B2 (en) 2016-06-17 2020-05-05 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
CN112839647B (zh) 2018-06-07 2025-09-23 达萨玛治疗公司 Sarm1抑制剂
CA3104808A1 (en) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Lactate enhancing compounds and uses thereof
US11248004B2 (en) 2018-11-06 2022-02-15 Cervello Therapeutics, Llc. Substituted isoquinolines as rock kinase inhibitors
BR112021008883A2 (pt) * 2018-11-06 2021-08-10 Cervello Therapeutics, Llc inibidores de rock quinase
CA3132228A1 (en) 2019-03-01 2020-09-10 Beijing Tide Pharmaceutical Co., Ltd. Method for treating fatty liver disease and/or steatohepatitis
ES3043933T3 (en) 2019-03-22 2025-11-26 Saniona As Novel potassium channel inhibitors
WO2021087112A1 (en) 2019-10-30 2021-05-06 Biogen Ma Inc. Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
CN115974647B (zh) * 2022-12-05 2024-09-03 江苏宏邦化工科技有限公司 以四氢-4-甲基-2-苯基-2h-吡喃-4-醇为原料制备苯乐戊醇的方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
JPH07277979A (ja) * 1994-04-12 1995-10-24 Asahi Chem Ind Co Ltd 過粘性症候群治療または予防剤
AU4144400A (en) 1999-04-27 2000-11-10 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
NZ524212A (en) * 2000-08-11 2004-07-30 Purdue Research Foundation Process for the preparation of dinapsoline
AR036492A1 (es) * 2001-09-06 2004-09-15 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes
CA2473510A1 (en) * 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
ATE441641T1 (de) * 2005-06-28 2009-09-15 Sanofi Aventis Isochinolinderivate als inhibitoren von rho- kinase
EP2385047B1 (en) 2005-07-26 2013-05-29 Sanofi Piperidinyl-substituted isoquinolone derivatives
ES2372067T3 (es) 2005-07-26 2012-01-13 Sanofi Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa.
US7867999B1 (en) * 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
WO2008077553A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
JP5405316B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノリン誘導体
HRP20100705T1 (hr) 2006-12-27 2011-01-31 Sanofi-Aventis Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati
RU2455302C2 (ru) 2006-12-27 2012-07-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
DE602007013295D1 (de) * 2006-12-27 2011-04-28 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
WO2008077552A1 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
CL2008000973A1 (es) * 2007-04-05 2009-01-02 Astrazeneca Ab Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
RU2538588C2 (ru) 2008-06-24 2015-01-10 Санофи-Авентис ЗАМЕЩЕННЫЕ ИЗИХИНОЛИНЫ И ИЗОХИНОЛИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
PT2303845E (pt) 2008-06-24 2013-11-25 Sanofi Sa Derivados de isoquinolina e isoquinolina substituída com bi- e policíclicos como inibidores de rho-cinase
CA2728128C (en) 2008-06-24 2016-06-07 Sanofi-Aventis 6-substituted isoquinolines and isoquinolinones

Also Published As

Publication number Publication date
SG11201605662TA (en) 2016-08-30
ZA201604976B (en) 2022-05-25
TWI547484B (zh) 2016-09-01
UA117953C2 (uk) 2018-10-25
EP3107900B1 (fr) 2017-11-15
EP3107900A1 (fr) 2016-12-28
PL3107900T3 (pl) 2018-04-30
MX363301B (es) 2019-03-20
MY178745A (en) 2020-10-20
MA39207A1 (fr) 2017-04-28
CA2938344A1 (fr) 2015-08-27
HK1232220A1 (zh) 2018-01-05
CY1120034T1 (el) 2018-12-12
ES2659885T3 (es) 2018-03-19
NO3107900T3 (cg-RX-API-DMAC10.html) 2018-04-14
JP6491226B2 (ja) 2019-03-27
RU2016137502A (ru) 2018-03-27
EA030617B1 (ru) 2018-08-31
AU2015220659A1 (en) 2016-08-04
KR102251198B1 (ko) 2021-05-11
US9809553B2 (en) 2017-11-07
IL246721B (en) 2018-12-31
PT3107900T (pt) 2018-01-08
JO3372B1 (ar) 2019-03-13
HUE038337T2 (hu) 2018-10-29
TW201534587A (zh) 2015-09-16
MX2016010779A (es) 2016-10-26
RS56766B1 (sr) 2018-04-30
AR099493A1 (es) 2016-07-27
RU2679621C2 (ru) 2019-02-12
EA201691675A1 (ru) 2017-02-28
ME02863B (me) 2018-04-20
CL2016002089A1 (es) 2017-01-27
FR3017868A1 (fr) 2015-08-28
WO2015124877A1 (fr) 2015-08-27
US20170137385A1 (en) 2017-05-18
RU2016137502A3 (cg-RX-API-DMAC10.html) 2018-09-24
AU2015220659B2 (en) 2018-09-13
NZ722513A (en) 2019-08-30
BR112016017679B1 (pt) 2022-07-26
DK3107900T3 (en) 2018-02-19
SI3107900T1 (en) 2018-02-28
CN105980361A (zh) 2016-09-28
UY35997A (es) 2015-08-31
LT3107900T (lt) 2017-12-27
CA2938344C (fr) 2018-07-03
HRP20180141T1 (hr) 2018-03-09
KR20160116003A (ko) 2016-10-06
CN105980361B (zh) 2019-05-21
JP2017506251A (ja) 2017-03-02

Similar Documents

Publication Publication Date Title
BR112016017664A2 (cg-RX-API-DMAC10.html)
BR112016018555A2 (cg-RX-API-DMAC10.html)
BR112016017283A2 (cg-RX-API-DMAC10.html)
BR112016016308A2 (cg-RX-API-DMAC10.html)
BR112016018238A2 (cg-RX-API-DMAC10.html)
BR112016018633A2 (cg-RX-API-DMAC10.html)
BR112016017207A2 (cg-RX-API-DMAC10.html)
BR112016016451A2 (cg-RX-API-DMAC10.html)
BR112016018185A2 (cg-RX-API-DMAC10.html)
BR112016016558A2 (cg-RX-API-DMAC10.html)
BR112016016372A2 (cg-RX-API-DMAC10.html)
BR112016016467A2 (cg-RX-API-DMAC10.html)
BR112016018510A2 (cg-RX-API-DMAC10.html)
BR112016017960A2 (cg-RX-API-DMAC10.html)
BR112016018632A2 (cg-RX-API-DMAC10.html)
BR112016017927A2 (cg-RX-API-DMAC10.html)
BR112016026073A2 (cg-RX-API-DMAC10.html)
RU2016137502A3 (cg-RX-API-DMAC10.html)
BR112016017130A2 (cg-RX-API-DMAC10.html)
BR112016018337A2 (cg-RX-API-DMAC10.html)
BR112016016522A2 (cg-RX-API-DMAC10.html)
BR112016018014A2 (cg-RX-API-DMAC10.html)
BR112016016348A2 (cg-RX-API-DMAC10.html)
BR112016015527A2 (cg-RX-API-DMAC10.html)
BR112016017695A2 (cg-RX-API-DMAC10.html)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/02/2015, OBSERVADAS AS CONDICOES LEGAIS